[HTML][HTML] IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2
…, C Thomas, E Laprevotte, C Garbar, AM Savoye… - Scientific reports, 2013 - nature.com
The proinflammatory cytokine Interleukin 17A (hereafter named IL–17A) or IL-17A producing
cells are elevated in breast tumors environment and correlate with poor prognosis …
cells are elevated in breast tumors environment and correlate with poor prognosis …
[HTML][HTML] Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
C Falandry, B Weber, AM Savoye, F Tinquaut… - Annals of oncology, 2013 - Elsevier
Background Two previous GINECO elderly specific studies in advanced ovarian cancer
(AOC) patients highlighted the prognostic value of geriatric covariates for overall survival …
(AOC) patients highlighted the prognostic value of geriatric covariates for overall survival …
Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO/GCIG …
…, F Tinquaut, D Lorusso, J Herrstedt, AM Savoye… - JAMA …, 2021 - jamanetwork.com
Importance Single-agent carboplatin is often proposed instead of a conventional carboplatin–
paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could …
paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could …
[HTML][HTML] Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study
…, D Berton-Rigaud, O Trédan, M Fabbro, AM Savoye… - Annals of …, 2019 - Elsevier
Background Few data are available on long-term fatigue (LTF) and quality of life (QoL)
among epithelial ovarian cancer survivors (EOCS). In this case–control study, we compared …
among epithelial ovarian cancer survivors (EOCS). In this case–control study, we compared …
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a …
…, J Grenier, F Dalenc, C Levy, AM Savoye… - JAMA …, 2023 - jamanetwork.com
Importance InERBB2 (formerlyHER2)-positive metastatic breast cancer (MBC), combining
trastuzumab and pertuzumab with taxane-based chemotherapy is the first line of standard …
trastuzumab and pertuzumab with taxane-based chemotherapy is the first line of standard …
Final results from a phase III randomized clinical trial of adjuvant endocrine therapy±chemotherapy in women≥ 70 years old with ER+ HER2-breast cancer and a high …
…, S Kirscher, D Allouache, V D'hondt, AM Savoye… - 2022 - ascopubs.org
500 Background: Benefit of adjuvant chemotherapy (CT) in addition to endocrine therapy
(ET) remains controversial for patients (pts) aged≥ 70 years with oestrogen receptors …
(ET) remains controversial for patients (pts) aged≥ 70 years with oestrogen receptors …
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A …
C Falandry, AM Savoye, L Stefani, F Tinquaut… - 2019 - ascopubs.org
5508 Background: The Geriatric Vulnerability Score (GVS) combining albumin, lymphocyte
count, ADL, IADL and HADS scores has been reported (Falandry C Ann Oncol 2013) to …
count, ADL, IADL and HADS scores has been reported (Falandry C Ann Oncol 2013) to …
Impact of chemotherapy-induced menopause in women of childbearing age with non-metastatic breast cancer–preliminary results from the MENOCOR study
J Passildas, O Collard, AM Savoye, J Dohou… - Clinical breast …, 2019 - Elsevier
Background Young patients with breast cancer treated with chemotherapy can experience
ovarian failure, which can lead to chemotherapy-induced menopause (CIM) impacting the …
ovarian failure, which can lead to chemotherapy-induced menopause (CIM) impacting the …
[HTML][HTML] Real-world experience of bevacizumab as first-line treatment for ovarian cancer: the GINECO ENCOURAGE cohort of 468 French patients
…, P Toussaint, R Largillier, AM Savoye… - Frontiers in …, 2021 - frontiersin.org
Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line
option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The …
option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The …
[HTML][HTML] Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol …
…, L Perrier, JM Grellard, I Licaj, B Clarisse, AM Savoye… - BMC cancer, 2021 - Springer
Background Germ cell tumors and sex cord stromal tumors are rare cancers of the ovary.
They mainly affect young women and are associated with a high survival rate. The standard …
They mainly affect young women and are associated with a high survival rate. The standard …